FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Clinical trials for FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for advanced endometrial cancer
Disease control OngoingThis study tests whether adding the drug ipatasertib to standard hormone therapy (megestrol acetate) can help control recurrent or metastatic endometrioid endometrial cancer. About 96 adults with grade 1 or 2 cancer that has returned or spread will participate. The goal is to see…
Matched conditions: FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:56 UTC
-
Can a birth control IUD plus a cancer pill replace hysterectomy?
Disease control OngoingThis study tests whether a hormone-releasing IUD (Mirena) alone or combined with the drug everolimus can treat precancerous changes or very early-stage endometrial cancer. About 102 women with these conditions will receive the IUD, and if it doesn't work after 3 months, some also…
Matched conditions: FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New hope for ovarian cancer: drug combo targets resistant tumors
Disease control OngoingThis early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The goal is to find the safest dose and see if the combo can shrink tumors or slow their gr…
Matched conditions: FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
Remote exercise program aims to boost strength in rural cancer survivors
Symptom relief OngoingThis study tests a 10-week home exercise program for endometrial cancer survivors who live in rural areas or are from underserved groups. Participants do strength training twice a week using a video call. The goal is to see if the program is practical and helps improve physical f…
Matched conditions: FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated May 15, 2026 12:07 UTC
-
New study aims to predict cancer return in Low-Risk patients
Knowledge-focused OngoingThis study looks at whether molecular testing and lymph node mapping can help predict if endometrial cancer will return in people with low-risk cancer. About 518 participants who are scheduled for surgery will be followed for two years. The goal is to improve how doctors estimate…
Matched conditions: FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 22, 2026 13:51 UTC